Accessibility Menu
Freeline Therapeutics Plc logo

Freeline Therapeutics Plc(NASDAQ) FRLN

This security has been delisted. This page is retained for historical reference.

Freeline Therapeutics Plc last closing stock price
MetricPriceDate
Last closeUSD 6.482024-02-16
Freeline Therapeutics Plc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.78%USD 6.432024-02-09
1 month+1.73%USD 6.372024-01-17
3 month+29.08%USD 5.022023-11-17
Year to date+1.73%USD 6.372023-12-29
1 year-20%USD 8.102023-02-16
3 year-97.27%USD 237.002021-02-16
Since inception-97.6%USD 270.002020-08-07

FRLN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

FRLN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-102.94%

Return on Capital

-168.75%

Return on Assets

-102.69%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

-$836.41K

Operating Income

-$67.88M

EBITDA

-$84.22M

Operating Cash Flow

-$64.24M

Capital Expenditure

-$4.55M

Free Cash Flow

-$68.79M

Cash & ST Invst.

$29.45M

Total Debt

$3.99M

Freeline Therapeutics Plc Performance Analysis

Freeline Therapeutics Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 0N/A
Freeline Therapeutics Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31N/A
Q12023-03-31N/A
Q22023-06-30N/A
Q32023-09-30-99.2%
Freeline Therapeutics Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -58.97N/A
20222022-12-31USD -22.50-61.8%
Freeline Therapeutics Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31-54.4%
Q12023-03-31105.6%
Q22023-06-30-1330.0%
Q32023-09-3024.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$5.00K

N/A

Gross Profit

-$378.76K

+5.9%

Gross Margin

-75.75%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

152

N/A

Net Income

-$12.09M

+18.8%

EBITDA

-$11.56M

+48.7%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$29.45M

-55.3%

Total Debt

$3.99M

-66.7%

Accounts Receivable

$2.82M

-4.8%

Inventory

$768.00K

-81.0%

Long Term Debt

$1.70M

-81.2%

Short Term Debt

$2.29M

-20.7%

Return on Assets

-1.03%

N/A

Return on Invested Capital

-1.77%

N/A

Free Cash Flow

-$8.68M

+50.0%

Operating Cash Flow

-$8.67M

+42.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ALLKAllakos Inc.
$0.33+0.22%
ANPCAnPac Bio-Medical Science Co., Ltd.
$4.30-3.15%
LMNLLiminal BioSciences Inc.
$8.50+0.12%
MRNSMarinus Pharmaceuticals, Inc.
$0.55+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
SQQQProShares Trust - ProShares UltraPro Short Qqq
$41.43-0.05%
NVDANvidia
$206.64+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.81+0.07%
INTCIntel
$91.00+0.01%

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.